Together, targeting of BRD4 and MYC through BET degradation sensitizes CML cells against BCR::ABL1 TKI and is a potent approach to overcome multiple forms of drug resistance in CML LSC. Here, BRD4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.